A-FIB
MCID: ATR011
MIFTS: 69

Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 37 29 55 6 43 3 44 15 63 63 73
Fibrillation, Atrial 40
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
ICD9CM 35 427.31
MeSH 44 D001281
NCIt 50 C50466
SNOMED-CT 68 49436004
KEGG 37 H00731
UMLS 73 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 63 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm.AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly.In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should.People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid.AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to familial atrial fibrillation and congestive heart failure, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Amiodarone and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 43 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Electrical activity of a normal heart (left) and a heart with atrial fibrillation (right).

Wikipedia : 76 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 familial atrial fibrillation 34.0 ABCC9 GJA5 KCNA5 KCNE2 KCNH2 KCNJ2
2 congestive heart failure 31.2 ACE ADRB1 NPPA NPPB
3 progressive familial heart block, type ia 31.2 GJA5 SCN5A
4 atrioventricular block 31.1 KCNE2 KCNH2 KCNQ1 NPPB SCN5A
5 myocardial infarction 31.1 ABCC9 ACE ADRB1 NPPA NPPB
6 mitral valve insufficiency 31.0 ACE NPPA NPPB
7 cardiac conduction defect 31.0 KCNH2 KCNQ1 SCN5A
8 left bundle branch hemiblock 30.9 ACE NPPB SCN5A
9 coronary artery anomaly 30.9 ACE ADRB1 NPPA NPPB
10 systolic heart failure 30.9 ACE ADRB1 NPPB
11 heart disease 30.9 ACE ADRB1 GJA5 KCNE2 KCNH2 KCNJ2
12 acute myocardial infarction 30.8 ACE ADRB1 NPPA NPPB
13 right bundle branch block 30.8 SCN1B SCN2B SCN3B SCN5A
14 brugada syndrome 30.7 ABCC9 KCNA5 KCNE2 KCNH2 KCNQ1 SCN1B
15 syncope 30.7 KCNH2 KCNJ2 KCNQ1 NPPA NPPB SCN5A
16 cardiac arrhythmia 30.7 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
17 ventricular fibrillation, paroxysmal familial, 1 30.7 KCNE2 KCNH2 KCNQ1 SCN5A
18 short qt syndrome 30.6 KCNE2 KCNH2 KCNJ2 KCNQ1
19 aortic valve disease 2 30.6 ACE MYL4 NPPA NPPB
20 central sleep apnea 30.6 NPPA NPPB
21 diastolic heart failure 30.5 ACE NPPA NPPB
22 catecholaminergic polymorphic ventricular tachycardia 30.5 KCNH2 KCNJ2 SCN5A
23 cardiac arrest 30.4 ACE KCNH2 KCNQ1 NPPB SCN5A
24 pulmonary hypertension 30.4 ACE KCNA5 NPPA NPPB
25 third-degree atrioventricular block 30.4 KCNE2 NPPB SCN5A
26 hypertension, essential 30.3 ACE ADRB1 NPPA NPPB
27 atrial standstill 1 30.3 ACE ADRB1 GJA5 NPPB SCN1B SCN5A
28 first-degree atrioventricular block 30.3 GJA5 SCN5A
29 coronary heart disease 1 30.3 ACE ADRB1 NPPB
30 dilated cardiomyopathy 30.2 ABCC9 ACE ADRB1 GJA5 KCNH2 KCNQ1
31 long qt syndrome 30.2 ADRB1 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
32 atrial standstill 30.2 GJA5 NPPA SCN5A
33 tetralogy of fallot 30.2 GJA5 KCNH2 NPPA NPPB
34 anterolateral myocardial infarction 30.1 ACE NPPA NPPB
35 pulmonary edema 30.0 ACE NPPA NPPB
36 chagas disease 30.0 ACE ADRB1 NPPB
37 timothy syndrome 29.9 KCNH2 KCNQ1
38 atrial fibrillation, familial, 15 12.6
39 atrial fibrillation, familial, 3 12.6
40 atrial fibrillation, familial, 4 12.6
41 atrial fibrillation, familial, 6 12.6
42 atrial fibrillation, familial, 7 12.6
43 atrial fibrillation, familial, 9 12.6
44 atrial fibrillation, familial, 10 12.6
45 atrial fibrillation, familial, 11 12.6
46 atrial fibrillation, familial, 12 12.6
47 atrial fibrillation, familial, 13 12.6
48 atrial fibrillation, familial, 14 12.6
49 atrial fibrillation, familial, 18 12.6
50 atrial fibrillation, familial, 1 12.5

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.98 MYL4
2 Decreased viability GR00402-S-2 9.98 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
3 no effect GR00402-S-1 9.62 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2

MGI Mouse Phenotypes related to Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNH2
2 homeostasis/metabolism MP:0005376 9.8 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
3 muscle MP:0005369 9.28 ABCC9 ADRB1 GJA5 KCNA5 KCNH2 KCNJ2

Drugs & Therapeutics for Atrial Fibrillation

PubMedHealth treatment related to Atrial Fibrillation: 63

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease. General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 604)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1951-25-3 2157
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
3 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
4
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
5
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 503612-47-3 10182969
6
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
7
Propafenone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54063-53-5 4932
8
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 959-24-0, 3930-20-9 5253
9
Carvedilol Approved, Investigational Phase 4,Phase 3,Not Applicable 72956-09-3 2585
10
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
12
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 113665-84-2, 120202-66-6 60606
13
Ticagrelor Approved Phase 4,Phase 3,Phase 1 274693-27-5 9871419
14
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 42399-41-7 39186
15
Phytonadione Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 84-80-0 4812 5284607
16 Edoxaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 480449-70-5
17
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
18
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
19
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 152-72-7 9052 54676537
20
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
21
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
27
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
28
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
29
Dalteparin Approved Phase 4,Phase 3,Phase 2 9005-49-6
30 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
31
Amlodipine Approved Phase 4,Not Applicable 88150-42-9 2162
32
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
33
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
34
Simvastatin Approved Phase 4,Phase 2,Not Applicable 79902-63-9 54454
35
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
36
Enalapril Approved, Vet_approved Phase 4,Phase 3,Not Applicable 75847-73-3 5362032 40466924
37
Eplerenone Approved Phase 4,Phase 3,Phase 2 107724-20-9 443872 150310
38
Lisinopril Approved, Investigational Phase 4,Not Applicable 83915-83-7, 76547-98-3 5362119
39
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2 137862-53-4 60846
40
Nebivolol Approved, Investigational Phase 4,Not Applicable 99200-09-6, 152520-56-4, 118457-14-0 71301
41
Spironolactone Approved Phase 4,Phase 3,Phase 2,Not Applicable 52-01-7, 1952-01-7 5833
42
Ramipril Approved Phase 4,Phase 2,Phase 3,Not Applicable 87333-19-5 5362129
43
Enalaprilat Approved Phase 4,Phase 3,Not Applicable 76420-72-9 6917719
44
Bisoprolol Approved Phase 4,Early Phase 1,Not Applicable 66722-44-9 2405
45
Captopril Approved Phase 4,Not Applicable 62571-86-2 44093
46
Candesartan cilexetil Approved Phase 4,Phase 3 145040-37-5 2540
47
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
48
Ibutilide Approved Phase 4,Not Applicable 122647-32-9, 122647-31-8 60753
49
Digoxin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 20830-75-5 30322 2724385
50
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 7487-88-9 24083

Interventional clinical trials:

(show top 50) (show all 2580)
# Name Status NCT ID Phase Drugs
1 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
2 Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
3 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
4 Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
5 The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation Unknown status NCT02808897 Phase 4
6 AF Ablation With or Without ROX Coupler Study Unknown status NCT02243891 Phase 4
7 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
8 AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation Unknown status NCT02341105 Phase 4 Amiodarone
9 The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
10 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study Unknown status NCT01504451 Phase 4
11 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
12 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
13 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
14 Rate Control in Atrial Fibrillation Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
15 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
16 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
17 Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
18 Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation Unknown status NCT01113294 Phase 4
19 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
20 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
21 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
22 Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins Unknown status NCT00605748 Phase 4
23 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
24 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
25 Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
26 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation Unknown status NCT02475642 Phase 4
27 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
28 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
29 ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON) Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
30 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
31 Comparison Between Contact Force Guided and Blinded Strategy on PV Isolation in AF Patients Unknown status NCT02924181 Phase 4
32 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4 irbesartan;placebo
33 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
34 Corticosteroid Pulse After Ablation Unknown status NCT00807586 Phase 4 Solumedrol;Placebo
35 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
36 Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
37 Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin" Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
38 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
39 Catheter Contact Force and Electrograms Unknown status NCT01587404 Phase 4
40 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
41 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
42 SmartTouch Catheter for Left Anterior Line - SmarT Line Study Unknown status NCT02217657 Phase 4
43 The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT Unknown status NCT00959205 Phase 4
44 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
45 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
46 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
47 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4 aliskiren
48 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
49 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
50 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

41
Heart, Testes, Brain, Lung, Kidney, Endothelial, Liver

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 4517)
# Title Authors Year
1
Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. ( 30539748 )
2019
2
Hemorrhagic Transformation After Acute Ischemic Stroke in Atrial Fibrillation Patients. ( 30539757 )
2019
3
Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the Management of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. ( 30550473 )
2019
4
Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort. ( 30554492 )
2019
5
Noninvasive mapping before surgical ablation for persistent, long-standing atrial fibrillation. ( 30482525 )
2019
6
Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry. ( 30487057 )
2019
7
Ablation of persistent atrial fibrillation and beyond. ( 30516581 )
2019
8
Cryoballoon ablation beyond paroxysmal atrial fibrillation. ( 30444759 )
2019
9
Comparing radiofrequency and cryoballoon technology for the ablation of atrial fibrillation. ( 30444763 )
2019
10
Trimethylamine N-oxide: A new therapeutic target for atrial fibrillation? ( 30449329 )
2019
11
Atrial Fibrillation and Heart Failure in Women. ( 30449380 )
2019
12
Late onset cardiac cirrhosis and portal hypertensive ascites after atrial fibrillation ablation. ( 30419795 )
2019
13
Ankylosing spondylitis: A novel risk factor for atrial fibrillation - A nationwide population-based study. ( 30360993 )
2019
14
Pulse rate variability predicts atrial fibrillation and cerebrovascular events in a large, population-based cohort. ( 30318296 )
2019
15
Relative contribution of modifiable risk factors for incident atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites. ( 30340851 )
2019
16
Atrial fibrillation in acute coronary syndromes: Could white blood cell count be the link? ( 30266351 )
2019
17
One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. ( 30291008 )
2019
18
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention. ( 30293674 )
2019
19
Does renal function have incremental predictive value of stroke in atrial fibrillation? ( 30190160 )
2019
20
Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration. ( 30217428 )
2019
21
Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. ( 30144994 )
2019
22
Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator? ( 30177235 )
2019
23
Increase in white blood cell count is associated with the development of atrial fibrillation after an acute coronary syndrome. ( 29936044 )
2019
24
Atrial fibrillation and stroke risk factors induce decline in creatinine clearance: Is there a specific "fibrillatory kidney disease"? ( 29306477 )
2018
25
Acute pericarditis following second-generation cryoballoon ablation for atrial fibrillation. ( 29445985 )
2018
26
Detecting cerebrovascular changes in the brain caused by hypertension in atrial fibrillation group using acoustocerebrography. ( 29979716 )
2018
27
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. ( 29447773 )
2018
28
Atrial Fibrillation Characteristics in Patients on Haemodialysis vs. Peritoneal Dialysis. ( 29445225 )
2018
29
Toll-Like Receptors 2 and 4 Predict New-Onset Atrial Fibrillation in Acute Myocardial Infarction Patients. ( 29375116 )
2018
30
Atrial fibrillation in acute Chagas disease acquired via oral transmission: a case report. ( 29972578 )
2018
31
Rhythm control better prevents stroke and mortality than rate control strategies in patients with atrial fibrillation - A nationwide cohort study. ( 29980369 )
2018
32
Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. ( 29444969 )
2018
33
Preventing Postoperative Atrial Fibrillation: is There One Best Option? ( 29452262 )
2018
34
Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan. ( 29975405 )
2018
35
Analysis of Haematological and Biochemical Blood Parameters After Electrical Cardioversion of Atrial Fibrillation in Dogs. ( 29978135 )
2018
36
Hypertension, mitral valve disease, atrial fibrillation and low education level predict delirium and worst outcome after cardiac surgery in older adults. ( 29390969 )
2018
37
Atrial fibrillation and stroke prevention: where we are and where we should be. ( 29853572 )
2018
38
Epicardial Fat Thickness and Free Fatty Acid Level are Predictors of Acute Ischemic Stroke with Atrial Fibrillation. ( 29971268 )
2018
39
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. ( 29447733 )
2018
40
Kohlmeier-Degos disease with constrictive pericarditis and atrial fibrillation. ( 29974345 )
2018
41
Uncontrolled blood pressure affects atrial remodeling and adverse clinical outcome in paroxysmal atrial fibrillation. ( 29446840 )
2018
42
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy? ( 29188358 )
2018
43
Letter regarding the article "Detecting atrial fibrillation by deep convolutional neural networks" by Xia et al. ( 29975853 )
2018
44
Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation. ( 29971208 )
2018
45
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. ( 29447772 )
2018
46
Prognostic value of von Willebrand factor in patients with atrial fibrillation: A meta-analysis. ( 29979393 )
2018
47
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. ( 29389037 )
2018
48
Incident Atrial Fibrillation and Stroke in Patients With Atrial Flutter. ( 29729880 )
2018
49
Screening for Atrial Fibrillation using Smartphone-based Technology and Layperson Volunteers: High-Tech Meets Community Participatory Research for the Best of Both Worlds. ( 29981478 )
2018
50
The unrecognized role of tumor suppressor genes in atrial fibrillation. ( 29126922 )
2018

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 40)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh37 Chromosome 11, 2549189: 2549189
2 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh38 Chromosome 11, 2527959: 2527959
3 KCNE2 NM_172201.1(KCNE2): c.79C> T (p.Arg27Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs74315449 GRCh37 Chromosome 21, 35742856: 35742856
4 KCNE2 NM_172201.1(KCNE2): c.79C> T (p.Arg27Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs74315449 GRCh38 Chromosome 21, 34370557: 34370557
5 SCN5A NM_000335.4(SCN5A): c.5958C> A (p.Asn1986Lys) single nucleotide variant Uncertain significance rs199473335 GRCh37 Chromosome 3, 38591902: 38591902
6 SCN5A NM_000335.4(SCN5A): c.5958C> A (p.Asn1986Lys) single nucleotide variant Uncertain significance rs199473335 GRCh38 Chromosome 3, 38550411: 38550411
7 SCN5A NM_198056.2(SCN5A): c.1333C> G (p.His445Asp) single nucleotide variant Uncertain significance rs199473112 GRCh37 Chromosome 3, 38647447: 38647447
8 SCN5A NM_198056.2(SCN5A): c.1333C> G (p.His445Asp) single nucleotide variant Uncertain significance rs199473112 GRCh38 Chromosome 3, 38605956: 38605956
9 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh37 Chromosome 3, 38646328: 38646328
10 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh38 Chromosome 3, 38604837: 38604837
11 SCN5A NM_000335.4(SCN5A): c.1282G> A (p.Glu428Lys) single nucleotide variant Uncertain significance rs199473111 GRCh37 Chromosome 3, 38647498: 38647498
12 SCN5A NM_000335.4(SCN5A): c.1282G> A (p.Glu428Lys) single nucleotide variant Uncertain significance rs199473111 GRCh38 Chromosome 3, 38606007: 38606007
13 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Likely pathogenic rs199473579 GRCh37 Chromosome 3, 38640469: 38640469
14 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Likely pathogenic rs199473579 GRCh38 Chromosome 3, 38598978: 38598978
15 KCNJ2 NM_000891.2(KCNJ2): c.277G> A (p.Val93Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs147750704 GRCh37 Chromosome 17, 68171457: 68171457
16 KCNJ2 NM_000891.2(KCNJ2): c.277G> A (p.Val93Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs147750704 GRCh38 Chromosome 17, 70175316: 70175316
17 SCN5A NM_000335.4(SCN5A): c.5848G> T (p.Val1950Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh37 Chromosome 3, 38592012: 38592012
18 SCN5A NM_000335.4(SCN5A): c.5848G> T (p.Val1950Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh38 Chromosome 3, 38550521: 38550521
19 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh37 Chromosome 11, 2549192: 2549192
20 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic/Likely pathogenic rs199472687 GRCh38 Chromosome 11, 2527962: 2527962
21 KCNQ1 NM_000218.2(KCNQ1): c.440A> G (p.Gln147Arg) single nucleotide variant not provided rs199472689 GRCh37 Chromosome 11, 2549211: 2549211
22 KCNQ1 NM_000218.2(KCNQ1): c.440A> G (p.Gln147Arg) single nucleotide variant not provided rs199472689 GRCh38 Chromosome 11, 2527981: 2527981
23 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh37 Chromosome 11, 2592575: 2592575
24 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh38 Chromosome 11, 2571345: 2571345
25 KCNH2 NM_000238.3(KCNH2): c.2690A> C (p.Lys897Thr) single nucleotide variant Benign/Likely benign rs1805123 GRCh37 Chromosome 7, 150645534: 150645534
26 KCNH2 NM_000238.3(KCNH2): c.2690A> C (p.Lys897Thr) single nucleotide variant Benign/Likely benign rs1805123 GRCh38 Chromosome 7, 150948446: 150948446
27 KCNE2 NM_172201.1(KCNE2): c.269A> G (p.Glu90Gly) single nucleotide variant not provided rs199473366 GRCh37 Chromosome 21, 35743046: 35743046
28 KCNE2 NM_172201.1(KCNE2): c.269A> G (p.Glu90Gly) single nucleotide variant not provided rs199473366 GRCh38 Chromosome 21, 34370747: 34370747
29 SCN5A NM_198056.2(SCN5A): c.3392C> T (p.Thr1131Ile) single nucleotide variant Uncertain significance rs199473197 GRCh37 Chromosome 3, 38618271: 38618271
30 SCN5A NM_198056.2(SCN5A): c.3392C> T (p.Thr1131Ile) single nucleotide variant Uncertain significance rs199473197 GRCh38 Chromosome 3, 38576780: 38576780
31 SCN5A NM_000335.4(SCN5A): c.414G> A (p.Met138Ile) single nucleotide variant Uncertain significance rs199473060 GRCh37 Chromosome 3, 38663959: 38663959
32 SCN5A NM_000335.4(SCN5A): c.414G> A (p.Met138Ile) single nucleotide variant Uncertain significance rs199473060 GRCh38 Chromosome 3, 38622468: 38622468
33 SCN5A NM_198056.2(SCN5A): c.4478A> G (p.Lys1493Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs199473260 GRCh37 Chromosome 3, 38597211: 38597211
34 SCN5A NM_198056.2(SCN5A): c.4478A> G (p.Lys1493Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs199473260 GRCh38 Chromosome 3, 38555720: 38555720
35 SCN5A NM_198056.2(SCN5A): c.5476C> T (p.Arg1826Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs199473635 GRCh37 Chromosome 3, 38592387: 38592387
36 SCN5A NM_198056.2(SCN5A): c.5476C> T (p.Arg1826Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs199473635 GRCh38 Chromosome 3, 38550896: 38550896
37 SCN5A NM_198056.2(SCN5A): c.5624T> C (p.Met1875Thr) single nucleotide variant Likely pathogenic rs199473324 GRCh37 Chromosome 3, 38592239: 38592239
38 SCN5A NM_198056.2(SCN5A): c.5624T> C (p.Met1875Thr) single nucleotide variant Likely pathogenic rs199473324 GRCh38 Chromosome 3, 38550748: 38550748
39 SCN5A NM_198056.2(SCN5A): c.5851G> A (p.Val1951Met) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh37 Chromosome 3, 38592012: 38592012
40 SCN5A NM_198056.2(SCN5A): c.5851G> A (p.Val1951Met) single nucleotide variant Conflicting interpretations of pathogenicity rs41315493 GRCh38 Chromosome 3, 38550521: 38550521

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

37
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 ADRB1 GJA5 SCN1B SCN2B SCN3B SCN4B
2
Show member pathways
12.63 ADRB1 KCNQ1 MYL4 SCN1B SCN4B SCN5A
3
Show member pathways
12.5 SCN1B SCN2B SCN3B SCN4B SCN5A
4
Show member pathways
12.46 ABCC9 KCNE2 KCNH2 KCNJ2 KCNQ1 MYL4
5 12.38 ADRB1 SCN1B SCN2B SCN5A
6 12.19 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
7
Show member pathways
12.01 ADRB1 KCNE2 KCNJ2 KCNQ1
8 12.01 KCNH2 KCNQ1 SCN3B SCN4B SCN5A
9
Show member pathways
11.94 ABCC9 KCNA5 KCNH2 KCNJ2 KCNQ1
10
Show member pathways
11.82 SCN1B SCN2B SCN3B SCN4B SCN5A
11
Show member pathways
11.57 KCNE2 KCNQ1 SCN1B SCN2B SCN3B SCN4B
12 11.51 ACE ADRB1 KCNJ2
13 11.18 ABCC9 ADRB1 GJA5 KCNA5 KCNE2 KCNH2
14 11.13 SCN1B SCN2B SCN3B SCN4B SCN5A
15 10.9 NPPA NPPB
16 10.82 KCNJ2 KCNQ1

GO Terms for Atrial Fibrillation

Cellular components related to Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.61 KCNA5 SCN3B SCN5A
2 voltage-gated potassium channel complex GO:0008076 9.55 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1
3 T-tubule GO:0030315 9.5 KCNJ2 SCN1B SCN5A
4 intercalated disc GO:0014704 9.43 GJA5 KCNA5 KCNJ2 SCN1B SCN4B SCN5A
5 voltage-gated sodium channel complex GO:0001518 9.02 SCN1B SCN2B SCN3B SCN4B SCN5A
6 membrane GO:0016020 10.27 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
7 plasma membrane GO:0005886 10.22 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2
8 integral component of membrane GO:0016021 10.13 ABCC9 ACE ADRB1 GJA5 KCNA5 KCNE2

Biological processes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 sodium ion transmembrane transport GO:0035725 9.98 SCN1B SCN2B SCN3B SCN4B SCN5A
2 regulation of ion transmembrane transport GO:0034765 9.96 KCNA5 KCNE2 KCNH2 KCNJ2 KCNQ1 SCN1B
3 regulation of sodium ion transmembrane transporter activity GO:2000649 9.88 SCN1B SCN2B SCN3B SCN4B
4 ventricular cardiac muscle cell action potential GO:0086005 9.88 GJA5 KCNE2 KCNH2 KCNQ1 SCN3B SCN5A
5 positive regulation of sodium ion transport GO:0010765 9.87 SCN1B SCN3B SCN4B SCN5A
6 cellular response to drug GO:0035690 9.86 KCNE2 KCNH2 KCNQ1
7 regulation of blood pressure GO:0008217 9.86 ACE NPPA NPPB
8 potassium ion export across plasma membrane GO:0097623 9.86 KCNA5 KCNE2 KCNH2 KCNQ1
9 potassium ion import across plasma membrane GO:1990573 9.85 ABCC9 KCNE2 KCNJ2
10 potassium ion export GO:0071435 9.85 KCNA5 KCNE2 KCNH2 KCNQ1
11 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.85 GJA5 SCN1B SCN2B SCN3B SCN5A
12 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.85 KCNJ2 SCN1B SCN2B SCN3B SCN4B SCN5A
13 potassium ion import GO:0010107 9.84 ABCC9 KCNE2 KCNJ2
14 regulation of membrane repolarization GO:0060306 9.84 KCNE2 KCNH2 KCNJ2 KCNQ1
15 membrane depolarization GO:0051899 9.83 SCN1B SCN3B SCN5A
16 positive regulation of heart rate GO:0010460 9.83 KCNQ1 NPPA SCN3B
17 membrane repolarization during action potential GO:0086011 9.83 KCNE2 KCNH2 KCNJ2 KCNQ1
18 atrial cardiac muscle cell action potential GO:0086014 9.83 KCNA5 KCNQ1 NUP155 SCN3B SCN5A
19 membrane depolarization during action potential GO:0086010 9.82 KCNH2 SCN3B SCN5A
20 positive regulation of potassium ion transmembrane transport GO:1901381 9.82 KCNH2 KCNJ2 KCNQ1
21 regulation of blood vessel diameter GO:0097746 9.81 ACE GJA5 NPPB
22 cardiac conduction GO:0061337 9.81 GJA5 SCN1B SCN3B
23 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE2 KCNH2 KCNQ1
24 membrane repolarization GO:0086009 9.8 KCNE2 KCNH2 KCNQ1
25 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.8 KCNA5 KCNQ1 NPPA SCN5A
26 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.79 KCNH2 KCNJ2 KCNQ1
27 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.77 GJA5 SCN3B SCN5A
28 SA node cell action potential GO:0086015 9.77 GJA5 SCN3B SCN5A
29 cardiac muscle contraction GO:0060048 9.76 KCNH2 KCNQ1 MYL4 SCN1B SCN2B SCN3B
30 regulation of vasoconstriction GO:0019229 9.71 ACE KCNA5
31 regulation of potassium ion transmembrane transport GO:1901379 9.71 KCNE2 KCNH2
32 regulation of blood vessel size GO:0050880 9.7 NPPA NPPB
33 potassium ion homeostasis GO:0055075 9.7 KCNA5 KCNH2
34 regulation of cardiac muscle cell contraction GO:0086004 9.7 KCNJ2 SCN5A
35 cGMP biosynthetic process GO:0006182 9.7 NPPA NPPB
36 positive regulation of cardiac muscle contraction GO:0060452 9.69 KCNQ1 NPPA
37 receptor guanylyl cyclase signaling pathway GO:0007168 9.69 NPPA NPPB
38 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.68 KCNA5 KCNQ1
39 AV node cell action potential GO:0086016 9.68 SCN4B SCN5A
40 response to pyrethroid GO:0046684 9.68 SCN1B SCN2B
41 AV node cell to bundle of His cell communication GO:0086067 9.66 GJA5 SCN5A
42 membrane depolarization during Purkinje myocyte cell action potential GO:0086047 9.66 SCN1B SCN5A
43 cardiac muscle cell action potential involved in contraction GO:0086002 9.5 KCNE2 KCNJ2 SCN1B SCN2B SCN3B SCN4B
44 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.17